Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up
| Autor: | Mesut Ayer, Saime Gul Barut, Emine Dervis, Asli Akin Belli |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors medicine.drug_class Population Antineoplastic Agents Dermatology Tyrosine-kinase inhibitor 030207 dermatology & venereal diseases 03 medical and health sciences Young Adult 0302 clinical medicine hemic and lymphatic diseases Leukemia Myelogenous Chronic BCR-ABL Positive medicine Edema Humans Hyperhidrosis Adverse effect education Stomatitis Aged Aged 80 and over education.field_of_study business.industry Myeloid leukemia Imatinib Alopecia Exanthema Middle Aged medicine.disease Rash Imatinib mesylate Cross-Sectional Studies Cheilitis 030220 oncology & carcinogenesis Imatinib Mesylate Female Stomatitis Aphthous Drug Eruptions medicine.symptom business Pigmentation Disorders medicine.drug Follow-Up Studies |
| Zdroj: | European journal of dermatology : EJD. 26(2) |
| ISSN: | 1952-4013 |
| Popis: | Imatinib is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML). Cutaneous adverse reactions of imatinib therapy have been reported in 7%-88.9% patients. We sought to evaluate the prevalence rates of cutaneous adverse reactions of imatinib therapy and to investigate the clinical and pathological characteristics of these reactions. Sixty-six patients (36 men, 30 women; age range 19-83 years) with CML treated with imatinib between 2008 and 2014 were included in the study. Clinical and pathological features of the adverse reactions were investigated. Cutaneous adverse reactions were the most common adverse effects of imatinib therapy and were seen in nine patients with a prevalence rate of 13.6%. The second most common adverse effect was musculoskeletal pain (12.1%). The following cutaneous reactions were observed in patients: edema, rash, pigmentary changes, aphthous stomatitis, alopecia, cutaneous dryness, hyperhidrosis and cheilitis. Imatinib therapy was discontinued in four patients because of various adverse effects. Although the prevalence rate of cutaneous adverse reactions in our study was lower than that in several other studies, cutaneous reactions were common in our study. The relatively low prevalence rate of adverse reactions may be related to the low dosage of imatinib (400 mg/day) used to treat our patients and may have been affected by pharmacogenetic characteristics of our population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink